Pluri re-initiated with a Buy at Alliance Global Partners

Alliance Global Partners analyst Matthew Venezia re-initiated coverage of Pluri (PLUR) with a Buy rating and $12 price target The company has transitioned from a clinical-stage cell therapy biotech with some novel bioreactor technology to a diversified biotech applying its “differentiated” bioreactor technology in multiple fields, the analyst tells investors in a research note. The firm says Pluri’s bioreactor system which solves many issues with current bioreactors related to scale up and production of cell-based products.